Measuring PDE4B in the brain and body with a new PET tracer in healthy adults
Official title: Evaluation of [11C]ZTP-1 to Image PDE4B
Run by National Institutes of Health Clinical Center (CC) · NCT07625345 · Data updated 2026-11-12
This study tests a new PET tracer, [11C]ZTP-1, to see if it can measure PDE4B levels in healthy adults.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 101 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Drugs / interventions | radiation |
| Locations | 1 site (Bethesda, Maryland) |
| Status | Recruiting |
| Started | July 1, 2026 |
| Main results expected | March 19, 2029 |
| Study ends | October 3, 2030 |
| Registry record updated | October 1, 2026 |
| Trial ID | NCT07625345 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Healthy adults aged 18 or older who have completed prior screening under protocol 01M-0254 or 17M0181 and meet all inclusion criteria.
✕Probably not a fit
Participants with significant medical conditions or abnormal baseline tests may not receive benefit from this research.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 1 study examines the brain uptake, distribution, and safety of the novel radioligand [11C]ZTP-1 in healthy volunteers. Participants will undergo one or two visits, including PET/CT imaging, blood and urine tests, and a cardiovascular check before tracer administration. Primary goals are to model the tracer’s brain kinetics and estimate PDE4B density, while secondary goals assess test–retest reliability, whole-body biodistribution, and radiation dose. The study is conducted at the NIH Clinical Center with participants screened under prior protocols and who meet health and consent criteria.
Why it matters
Potential benefit: If successful, the tracer could provide a more accurate measure of PDE4B in research and future clinical assessments.
How similar studies have gone: Previous work with PDE4B tracers has shown feasibility in PET imaging, but this specific tracer [11C]ZTP-1 aims to establish reliability and dosimetry in humans.
Who can join: the full rules
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: To be eligible to participate in this study, an individual must meet the following criteria: * Aged 18 years or older. * Must have undergone a screening assessment under protocol 01M-0254, "The Evaluation of Patients with Mood and Anxiety Disorders and Healthy Participants or protocol 17M0181 Recruitment and Characterization of Healthy Research Volunteers for NIMH Intramural Studies." * Be healthy based on medical history, physical examination, and laboratory testing. * Able to provide informed consent. * Willingness to complete all study procedures including MRI tests. * Have had their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists. * Agree to adhere to the lifestyle considerations EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: * Clinically significant abnormalities on EKG or laboratory testing. This includes CBC and acute care panel (Na, K, Cl, CO2, creatinine, glucose, urea nitrogen). * History of neurologic illness or injury with the potential to affect study data interpretation. * History of seizures, other than in childhood and related to fever. * Recent exposure to radiation (i.e., PET from other research) that, when combined with this study, would be above the allowable limits. * Inability to lie flat on camera bed for at least two hours, including claustrophobia and weight greater than the maximum for the scanner (500 lbs). * HIV infection. * Pregnancy or breastfeeding. * Must not have substance use disorder or alcohol use disorder. * Unable to travel to the NIH. * Unable to have an MRI scan (e.g., because of pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, shrapnel fragments, or metal fragments in the eye. * Known hypersensitivity to phosphodiesterase-4 (PDE-4) inhibitors (e.g. apremilast, roflumilast, nerandomilast, crisborole). * Taking CYP3A4 inhibitors (e.g. grapefruit juice, clarithromycin, erythromycin, ritonavir); CYP3A4 inducers (e.g. phenobarbital St. John's Wort, rifampicin) or oral contraceptives containing gestodene and ethinyl estradiol. EXCLUSION OF CHILDREN: Inclusion of children is not appropriate, because this protocol has more than minimal risk from radiation exposure without the possibility of direct benefit. EXCLUSION OF PREGNANT OR BREASTFEEDING WOMEN: Pregnant women will be excluded because this protocol involves exposure to ionizing radiation. Lactating women will be excluded because radioisotopes may be excreted in milk. We will perform a pregnancy test at screening and prior to all procedures to ensure participants are not pregnant. The test must be negative in order to continue on the study. In addition to completing a negative urine pregnancy test, on the day of PET scanning prior to PET scan procedures, participants of childbearing potential will undergo a clinical pregnancy screening interview with a licensed independent practitioner to confirm lack of pregnancy. EXCLUSION OF PARTICIPANTS WHO ARE HIV POSITIVE: Persons with HIV infection are excluded because HIV infection itself may change cAMP signaling.
Where it's running
-
National Institutes of Health Clinical Center
Bethesda, Maryland, United States Recruiting
Study contacts
- Principal investigator: Robert B Innis, M.D. — National Institute of Mental Health (NIMH)
- Study coordinator: Tara N Turon, C.R.N.P.
- Email: tara.turon@nih.gov
- Phone: (301) 827-6599
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Do Quercefit® or Ubiqsome™ help with aging and metabolic health in adults 50–75?
This study tests whether Quercefit® or Ubiqsome™ can improve aging markers, blood sugar, and heart health in sedentary adults aged 50–75 compared with a placebo.
-
NVTIA Ergothioneine for Healthy Aging and Skin Health
This study tests whether taking NVTIA Ergothioneine daily for 12 weeks helps healthy adults age more gracefully and keeps skin looking and feeling better compared with a placebo.
-
Miricell supplementation and markers of healthy aging
This trial tests whether taking Miricell once daily for 12 weeks improves cellular health and brain/metabolic indicators in adults aged 40–70 compared with a placebo.
-
Does daily lean beef support brain health in older adults
In healthy adults aged 65 and up, this study tests whether eating lean beef every day for two weeks can influence brain health markers compared with a non-beef, protein-matched option.
-
Adaptive computerized training to boost thinking in healthy seniors and those with mild cognitive impairment
This study tests whether a computer-based training program can improve executive thinking in older adults, including those with mild cognitive impairment, and see if it also helps memory and well-being.
-
SHARP: Personalized Health and Behavior Plan to Lower Biological Age in Older Adults
A 12-month randomized trial tests whether a personalized health and behavior program can lower biological age and improve function in healthy adults over 50.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.